Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies

Learning Goals

Immunotherapies in B-Cell Malignancies

Available Immunotherapies

OS in MM

Poor Outcome in High-Risk Myeloma

Immunotherapy Potential for Success Without a Targetable Molecular Mutation

Available Immunotherapies

Monoclonal Antibodies Approved for MM

Elotuzumab and Daratumumab

Daratumumab

Elotuzumab

Daratumumab Potential MOA

Daratumumab Monotherapy Phase 2 Study, ≥ 3 Lines of Prior Therapy

Daratumumab in Combination

CASTOR Study Daratumumab + Bor/Dex vs Bor/Dex

CASTOR Study Efficacy Endpoints and IRRs

POLLUX Daratumumab + Len/Dex vs Len/Dex

Elotuzumab MOA

ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

ELOQUENT-2

Therapies in Development Antibodies

Antibody Drug Conjugates

Brentuximab Vedotin

AETHERA Brentuximab Vedotin as Consolidation Therapy After ASCT in Patients With HL

Other ADCs in Development for MM

T-Cell Receptors Activating and Inhibitory

Checkpoint Inhibitors in HL

Checkpoint Inhibitors in MM

Structure of Chimeric Antigen Receptors

Clinical Trials With CAR-T Cells in MM

CAR-T Cell Therapy

Cytokine Release Syndrome (CRS)

Response to Tocilizumab in 2 Patients

Bispecific T-Cell Engagers

Patient-Specific Dendritic Cell/MM Cell Fusion Vaccines Postautologous Transplant

Response Rates After Vaccination

Future of Immunotherapeutic Strategies in B-Cell Malignancies

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)